U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C25H28N2O5S
Molecular Weight 468.565
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EVATANEPAG

SMILES

CC(C)(C)C1=CC=C(CN(CC2=CC=CC(OCC(O)=O)=C2)S(=O)(=O)C3=CN=CC=C3)C=C1

InChI

InChIKey=WOHRHWDYFNWPNG-UHFFFAOYSA-N
InChI=1S/C25H28N2O5S/c1-25(2,3)21-11-9-19(10-12-21)16-27(33(30,31)23-8-5-13-26-15-23)17-20-6-4-7-22(14-20)32-18-24(28)29/h4-15H,16-18H2,1-3H3,(H,28,29)

HIDE SMILES / InChI
Molecular Formula C25H28N2O5S
Molecular Weight 468.565
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Evatanepag (CP-533,536) is a prostaglandin E2 EP2 receptor agonist. It stimulates new bone formation on trabecular, endocortical, and periosteal surfaces and enhances fracture healing. Evatanepag was under development with Pfizer as a bone formation stimulant for therapeutic use in the healing of fractures.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2752
 5.0 nM [EC50]
PubMed

PubMed

TitleDatePubMed
Discovery of CP-533536: an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation.
2009-04-01
CYP2C8- and CYP3A-mediated C-demethylation of (3-{[(4-tert-butylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid (CP-533,536), an EP2 receptor-selective prostaglandin E2 agonist: characterization of metabolites by high-resolution liquid chromatography-tandem mass spectrometry and liquid chromatography/mass spectrometry-nuclear magnetic resonance.
2008-10
In vitro pharmacological characterization of CJ-042794, a novel, potent, and selective prostaglandin EP(4) receptor antagonist.
2008-01-16
Patents

Patents

20010056060
2
JP2009137934A
2
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:27:21 GMT 2025
Edited
by admin
on Mon Mar 31 18:27:21 GMT 2025
Record UNII
L266R6E31E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
EVATANEPAG
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
CP-533,536
Preferred Name English
ACETIC ACID, 2-(3-((((4-(1,1-DIMETHYLETHYL)PHENYL)METHYL)(3-PYRIDINYLSULFONYL)AMINO)METHYL)PHENOXY)-
Common Name English
2-(3-((((4-(1,1-DIMETHYLETHYL)PHENYL)METHYL)(PYRIDIN-3-YLSULFONYL)AMINO)METHYL)PHENOXY)ACETIC ACID
Systematic Name English
Evatanepag [WHO-DD]
Common Name English
CP-533536
Code English
evatanepag [INN]
Common Name English
EVATANEPAG [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C78568
Created by admin on Mon Mar 31 18:27:21 GMT 2025 , Edited by admin on Mon Mar 31 18:27:21 GMT 2025
Code System Code Type Description
EPA CompTox
DTXSID20945000
Created by admin on Mon Mar 31 18:27:21 GMT 2025 , Edited by admin on Mon Mar 31 18:27:21 GMT 2025
PRIMARY
CAS
223488-57-1
Created by admin on Mon Mar 31 18:27:21 GMT 2025 , Edited by admin on Mon Mar 31 18:27:21 GMT 2025
PRIMARY
DRUG BANK
DB12022
Created by admin on Mon Mar 31 18:27:21 GMT 2025 , Edited by admin on Mon Mar 31 18:27:21 GMT 2025
PRIMARY
NCI_THESAURUS
C83707
Created by admin on Mon Mar 31 18:27:21 GMT 2025 , Edited by admin on Mon Mar 31 18:27:21 GMT 2025
PRIMARY
SMS_ID
300000034247
Created by admin on Mon Mar 31 18:27:21 GMT 2025 , Edited by admin on Mon Mar 31 18:27:21 GMT 2025
PRIMARY
INN
9151
Created by admin on Mon Mar 31 18:27:21 GMT 2025 , Edited by admin on Mon Mar 31 18:27:21 GMT 2025
PRIMARY
PUBCHEM
9890801
Created by admin on Mon Mar 31 18:27:21 GMT 2025 , Edited by admin on Mon Mar 31 18:27:21 GMT 2025
PRIMARY
USAN
UU-103
Created by admin on Mon Mar 31 18:27:21 GMT 2025 , Edited by admin on Mon Mar 31 18:27:21 GMT 2025
PRIMARY
FDA UNII
L266R6E31E
Created by admin on Mon Mar 31 18:27:21 GMT 2025 , Edited by admin on Mon Mar 31 18:27:21 GMT 2025
PRIMARY
ChEMBL
CHEMBL563646
Created by admin on Mon Mar 31 18:27:21 GMT 2025 , Edited by admin on Mon Mar 31 18:27:21 GMT 2025
PRIMARY
Related Record Type Details
CYTOCHROME P450 2C8
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
Structure of EVATANEPAG SODIUM
SALT/SOLVATE -> PARENT
CYTOCHROME P450 3A5
METABOLIC ENZYME -> SUBSTRATE
PROSTAGLANDIN E2 RECEPTOR EP2 SUBTYPE
TARGET -> AGONIST
Related Record Type Details
Structure of OMEGA-HYDROXY EVATANEPAG
METABOLITE -> PARENT
IN VITRO
Structure of N-((4-(1,1-DIMETHYLETHYL)PHENYL)METHYL)-3-PYRIDINESULFONAMIDE
METABOLITE -> PARENT
IN VITRO
Structure of N-((4-(2-HYDROXY-1,1-DIMETHYLETHYL)PHENYL)METHYL)-3-PYRIDINESULFONAMIDE
METABOLITE -> PARENT
IN VITRO
Structure of DEMETHYL-HYDROXY-EVATANEPAG
METABOLITE -> PARENT
IN VITRO
Structure of PYRIDINE-N-OXIDE EVATANEPAG
METABOLITE -> PARENT
IN VITRO
Structure of N-((4-(1,1-DIMETHYLETHYL)PHENYL)METHYL)-3-PYRIDINE-1-OXIDE SULFONAMIDE
METABOLITE -> PARENT
IN VITRO
Structure of 2-METHYL-2-(4-((PYRIDIN-3-YLSULFONYLAMINO)METHYL)PHENYL)PROPIONIC ACID
METABOLITE -> PARENT
IN VITRO
Structure of 2-(3-((((4-(1-METHYLETHENYL)PHENYL)METHYL)(3-PYRIDINYLSULFONYL)AMINO)METHYL)PHENOXY)ACETIC ACID
METABOLITE -> PARENT
IN VITRO
Structure of 2-(4-(((3-CARBOXYMETHOXYBENZYL)-N-((PYRIDIN-3-YL)SULFONYL)AMINO)METHYL)PHENYL)-2-METHYLPROPIONIC ACID
METABOLITE -> PARENT
IN VITRO
Structure of OMEGA-HYDROXY-PYRIDINE-N-OXIDE EVATANEPAG
METABOLITE -> PARENT
IN VITRO
Structure of (3-(((4-(1,1-DIMETHYL-2-OXOETHYL)BENZYL)(PYRIDIN-3-YLSULFONYL)AMINO)METHYL)PHENOXY)ACETIC ACID
METABOLITE -> PARENT
IN VITRO
Structure of DEMETHYL-HYDROXY-OMEGA-HYDROXY EVATANEPAG
METABOLITE -> PARENT
IN VITRO
Related Record Type Details
Structure of EVATANEPAG
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966